Autoimmune myasthenia gravis

References

• Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr. Opin. Neurol.18, 519–525 (2005).
   PubMed Web of Science ®Google Scholar
• Leite MI, Jacob S, Viegas S et al. IgG1 antibodies to acetylcholine receptors in “seronegative” myasthenia gravis. Brain131, 1940–1952 (2008).
   PubMed Web of Science ®Google Scholar
• Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur. J. Neurol.14, 617–620 (2007).
   PubMed Web of Science ®Google Scholar
• Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr. Opin. Neurol.21, 8–15 (2008).
   PubMed Web of Science ®Google Scholar
• Skeie GO, Apostolski S, Evoli A et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol.31, 691–699 (2006).
   Google Scholar
• Skeie GO, Aarli JA, Gilhus NE. Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurol. Scand.113(Suppl. 183), 19–23 (2006).
   Web of Science ®Google Scholar
• Evoli A, Bianchi MR, Riso R et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann. NY Acad. Sci.1132, 76–83 (2008).
   PubMed Web of Science ®Google Scholar
• Chavis PS, Stickler DE, Walker A. Immunosuppressive or surgical treatment for ocular myasthenia gravis. Arch. Neurol.64, 1792–1794 (2007).
   PubMedGoogle Scholar
• Gilbert ME, De Sousa EA, Savino PJ. Ocular myasthenia gravis treatement. Arch. Neurol.64, 1790–1792 (2007).
   PubMedGoogle Scholar
• Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve29, 484–505 (2004).
   PubMed Web of Science ®Google Scholar
• Barohn RJ. Treatment and clinical research in myasthenia gravis: how far have we come? Ann. NY Acad. Sci.1131, 225–232 (2008).
   PubMed Web of Science ®Google Scholar
• Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve371, 141–149 (2008).
   Google Scholar
• Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nauret. Clin. Pract.4, 317–327 (2008).
   PubMedGoogle Scholar
• Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology50, 1778–1783 (1998).
   PubMed Web of Science ®Google Scholar
• Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. NY Acad. Sci.681, 539–551 (1993).
   PubMed Web of Science ®Google Scholar
• Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann. NY Acad. Sci.1132, 305–314 (2008).
   PubMed Web of Science ®Google Scholar
• Sanders DB, Siddiqi ZA. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann. NY Acad. Sci.1132, 249–253 (2008).
   PubMed Web of Science ®Google Scholar
• Ponseti JM, Gamez J, Azem J, lopez-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann. NY Acad. Sci.1132, 254–263 (2008).
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Cutter G, Wolfe GI et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann. NY Acad. Sci.1132, 344–347 (2008).
   PubMed Web of Science ®Google Scholar
• Gronseth GS, Barohn RJ. Thymectomy for autoimmune myasthenia gravis: an evidence-based review. Neurology55, 7–15 (2000).
   PubMed Web of Science ®Google Scholar
• Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol. Scand.111, 134–141 (2005).
   PubMed Web of Science ®Google Scholar
• Mantegazza R Baggi F, Bernasconi P et al. Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients; remission after 6-years follow-up. J. Neurol. Sci.212, 31–36 (2003).
   PubMed Web of Science ®Google Scholar
• Kondo K. Optimal therapy for thymoma. J. Med. Invest.55, 17–28 (2008).
   PubMedGoogle Scholar
• Hoff JM, Daltveit AK, Gilhus NE. Myasthenia in pregnancy and birth; identifying risk factors, optimizing care. Eur. J. Neurol.14, 38–43 (2007).
   PubMed Web of Science ®Google Scholar
• Hoff JM, Daltveit AK, Gilhus NE. Arthrogryposis multiplex congenital: a rare fetal condition caused by maternal myasthenia gravis. Acta Neurol. Scand.113(Suppl. 183), 26–27 (2006).
   Web of Science ®Google Scholar
• Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann. Neurol.41, 789–796 (1997).
   PubMed Web of Science ®Google Scholar
• Elovaara I, Apostolski S, van Doorn P et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol.15, 893–908 (2008).
   PubMed Web of Science ®Google Scholar
• Owe JF, Daltveit AK, Gilhus NE. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J. Neurol. Neurosurg. Psychiat.77, 203–207 (2006).
   PubMed Web of Science ®Google Scholar
• Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune myasthenia gravis. Ann. NY Acad. Sci.1132, 180–192 (2008).
   PubMed Web of Science ®Google Scholar
• Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J. Neuroimmunol.152, 112–120 (2004).
   PubMed Web of Science ®Google Scholar
• Faria AMC, Weiner HL. Oral tolerance. Immunol. Rev.206, 232–259 (2005).
   PubMed Web of Science ®Google Scholar
• Fostieri E, Kostelidou K, Poulas K, Tzartos SJ. Recent advances in the understanding and therapy of myasthenia gravis. Future Neurol.1, 799–817 (2006).
   Google Scholar
• Lindstrom J, Luo J, Kuryatov A. Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains. Ann. NY Acad. Sci.1132, 29–41 (2008).
   PubMed Web of Science ®Google Scholar
• Meriggioli MN, Sheng JR, Li L, Prabhakar BS. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann. NY Acad. Sci.1132, 276–282 (2008).
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Matsuo H, Sakuma H et al. CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis. J. Immunol.176, 5100–5107 (2006).
   PubMed Web of Science ®Google Scholar
• Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med.14, 748–755 (2008).
   PubMed Web of Science ®Google Scholar
• Tzartos SJ, Bitzopoulou K, Gavra I et al. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann. NY Acad. Sci.1132, 291–299 (2008).
   PubMed Web of Science ®Google Scholar
• Losen M, Martinez-Martinez P, Phernambucq M, Schuurman J, Parren PWHI, De Baets MH. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann. NY Acad. Sci.1132, 174–179 (2008).
   PubMed Web of Science ®Google Scholar
• Sussman JD, Argov Z, McKee D, Hazum E, Brawer S, Soreq H. Antisense treatment for myasthenia gravis: experience with monarsen. Ann. NY Acad. Sci.1132, 283–290 (2008).
   PubMed Web of Science ®Google Scholar
• Aricha R, Feferman T, Fuchs S. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB. J.20, 374–376 (2005).
   PubMed Web of Science ®Google Scholar